Yongping Yue
Overview
Explore the profile of Yongping Yue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
3059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Wasala N, Lai Y, Shin J, Zhao J, Yue Y, Duan D
Hum Mol Genet
. 2016 Apr;
25(13):2633-2644.
PMID: 27106099
Duchenne muscular dystrophy (DMD) is caused by dystrophin deficiency. A fundamental question in DMD pathogenesis and dystrophin gene therapy is whether muscle health depends on continuous dystrophin expression throughout the...
32.
Yue Y, Pan X, Hakim C, Kodippili K, Zhang K, Shin J, et al.
Hum Mol Genet
. 2015 Aug;
24(20):5880-90.
PMID: 26264580
The ultimate goal of muscular dystrophy gene therapy is to treat all muscles in the body. Global gene delivery was demonstrated in dystrophic mice more than a decade ago using...
33.
Pan X, Yue Y, Zhang K, Hakim C, Kodippili K, McDonald T, et al.
Hum Gene Ther Methods
. 2015 Mar;
26(2):54-61.
PMID: 25763686
Adeno-associated virus serotype-8 and 9 (AAV-8 and 9) are the leading candidate vectors to test bodywide neonatal muscle gene therapy in large mammals. We have previously shown that systemic injection...
34.
Hakim C, Yue Y, Shin J, Williams R, Zhang K, Smith B, et al.
Mol Ther Methods Clin Dev
. 2014 Aug;
1:14002.
PMID: 25105153
The muscular dystrophies are a group of devastating genetic disorders that affect both skeletal and cardiac muscle. An effective gene therapy for these diseases requires bodywide muscle delivery. Tyrosine mutant...
35.
Lostal W, Kodippili K, Yue Y, Duan D
Hum Gene Ther
. 2014 Mar;
25(6):552-62.
PMID: 24580018
Duchenne muscular dystrophy (DMD) is the most common lethal muscle disorder in children. It is caused by mutations of the dystrophin gene. Adeno-associated virus (AAV)-mediated gene replacement therapy has been...
36.
Kodippili K, Vince L, Shin J, Yue Y, Morris G, McIntosh M, et al.
PLoS One
. 2014 Feb;
9(2):e88280.
PMID: 24516626
Epitope-specific monoclonal antibodies can provide unique insights for studying cellular proteins. Dystrophin is one of the largest cytoskeleton proteins encoded by 79 exons. The absence of dystrophin results in Duchenne...
37.
Lai Y, Zhao J, Yue Y, Wasala N, Duan D
Hum Mol Genet
. 2014 Jan;
23(12):3189-99.
PMID: 24463882
Transgenic gene deletion/over-expression studies have established the cardioprotective role of neuronal nitric oxide synthase (nNOS). However, it remains unclear whether nNOS-mediated heart protection can be translated to gene therapy. In...
38.
Zhang Y, Yue Y, Li L, Hakim C, Zhang K, Thomas G, et al.
Hum Mol Genet
. 2013 May;
22(18):3720-9.
PMID: 23681067
Neuronal nitric oxide synthase (nNOS) membrane delocalization contributes to the pathogenesis of Duchenne muscular dystrophy (DMD) by promoting functional muscle ischemia and exacerbating muscle injury during exercise. We have previously...
39.
Pan X, Yue Y, Zhang K, Lostal W, Shin J, Duan D
Hum Gene Ther
. 2013 Apr;
24(6):584-94.
PMID: 23551085
Molecular intervention using noninvasive myocardial gene transfer holds great promise for treating heart diseases. Robust cardiac transduction from peripheral vein injection has been achieved in rodents using adeno-associated virus (AAV)...
40.
Wasala N, Bostick B, Yue Y, Duan D
Hum Mol Genet
. 2013 Mar;
22(13):2634-41.
PMID: 23459935
Duchenne muscular dystrophy (DMD) is characterized by severe degeneration and necrosis of both skeletal and cardiac muscle. While many experimental therapies have shown great promise in treating skeletal muscle disease,...